Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday’s episode of her podcast, “Pod Meets World,” that she is being treated for ductal carcinoma in situ. “It is ...

Soon after her diagnosis, Storm’s physician team ordered PreludeDx’s DCISionRT®, the only risk assessment test that predicts radiation therapy (RT) benefit in DCIS patients, to be run on her tumor ...

Watchful waiting appears to serve women with DCIS just as well as going ahead with surgery Women in active surveillance had the same rate of breast cancer as those who had surgery Both groups also had ...

Waiting and seeing is not often the strategy employed when it comes to treating breast cancer, but a new clinical trial by the University of California, San Francisco, researchers are doing just that.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The incidence of ...

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received ...

Patients with low-risk ductal carcinoma in situ (DCIS) who underwent active monitoring reported comparable physical, emotional, and psychological outcomes to patients who received upfront treatment, ...

SAN ANTONIO -- Active monitoring for low-risk ductal carcinoma in situ (DCIS) did not lead to a higher rate of ipsilateral invasive cancer versus guideline-recommended treatment, the randomized COMET ...

Thanks to better screening, the absolute number of DCIS cases has jumped seven-fold in the U.S. over the past three decades. “At the moment, we don’t know which women diagnosed with DCIS might be able ...

Dear Doctor K: I have been diagnosed with ductal carcinoma in situ. My doctor wants me to have surgery. But recently I read about a study that said not all women with this type of breast cancer even ...

LAGUNA HILLS, Calif., Feb. 12, 2025 /PRNewswire/ — Prelude Corporation (PreludeDx®), a leader in precision diagnostics for early-stage breast cancer, today announced a partnership with Hannah Storm, ...